Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab and Denosumab Combination in Postmenopausal Osteoporosis (MORD)
NCT06720350Phase 4Not yet recruiting
- Sponsor
- Marmara University
- Start
- Jan 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of romosozumab in postmenopausal osteoporosis (3 arms), sponsored by Marmara University. Primary endpoints: New Fracture and Bone Mineral Density at 1 year. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT06720350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720350.